22Apr 2022
Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppression

Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppression

Patients on chronic pharmacologic immunosuppressive therapy are at increased risk of wound infection and complications after surgery. Unfortunately, this patient population has a lack of data examining perioperative complications after microvascular free tissue transfer (MVFTT) reconstruction of the head and neck. A retrospective cohort study was performed at two tertiary referral centres between August 2016 and May 2020. Nine hundred and seventy‐nine patients underwent MVFTT during the study period; 47 (5%) patients were taking chronic immunosuppressive medications. The most common indications for immunosuppression were solid organ transplant and autoimmune disease. In addition, there was one total and one partial flap failure with a 30‐day reoperation rate of 4%. MVFTT of the head and neck appear to be safe in patients on chronic pharmacologic immunosuppression.

  • #ent

Like

Save

Share